In a study posted online Dec. 12 by Nature, scientists from Cincinnati Children's Hospital Medical Center say their findings will open the door to unprecedented studies of human intestinal development, function and disease. The process is also a significant step toward generating intestinal tissue for transplantation, researchers say.
"This is the first study to demonstrate that human pluripotent stem cells in a petri dish can be instructed to efficiently form human tissue with three-dimensional architecture and cellular composition remarkably similar to intestinal tissue," said James Wells, Ph.D., senior investigator on the study and a researcher in the division of Developmental Biology at Cincinnati Children's.
"The hope is that our ability to turn stem cells into intestinal tissue will eventually be therapeutically beneficial for people with diseases such as necrotizing enterocolitis, inflammatory bowel disease and short bowel syndromes," he added.
In the study, a team of scientists led by Dr. Wells and study first author Jason Spence, Ph.D. – a member of Dr. Wells' laboratory – used two types of pluripotent cells: human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs). iPSCs were generated by reprogramming biopsied human skin cells into pluripotent stem cells. This was done in collaboration with Cincinnati Children's researchers Susanne Wells, Ph.D., and Chris Mayhew, Ph.D., co-director of the institution's Pluripotent Stem Cell Facility.
hESCs are called pluripotent because of their ability to become any of the more than 200 different cell types in the human body. iPSCs can be generated from the cells of individual patients, and therapeutic cells derived from those iPSCs would have that person's genetic makeup and not be at risk of rejection. Because iPSC technology is new, it remains unknown if these cells have all of the potential of hESCs, Dr. Wells explained. This prompted the researchers to use both iPSCs and human embryonic stem cells in this study so they could further test and compare the transformative capabilities of each.
To turn pluripotent stem cells into intestinal tissue, scientists performed a timed series of cell manipulations using chemicals and proteins called growth factors to mimic embryonic intestinal development in the laboratory.
The first step turned pluripotent stem cells into an embryonic cell type called definitive endoderm, which gives rise to the lining of the esophagus, stomach and intestines as well as the lungs, pancreas and liver. Next, endoderm cells were instructed to become one those organ cell types, specifically embryonic intestinal cells called a "hindgut progenitors". The researchers then subjected the cells to what they describe as a "pro-intestinal" cell culture system that promoted intestinal growth.
Within 28 days, these steps resulted in the formation of three-dimensional tissue resembling fetal intestine that contained all the major intestinal cell types – including enterocytes, goblet, Paneth and enteroendocrine cells. The tissue continued to mature and acquire both the absorptive and secretory functionality of normal human intestinal tissues and also formed intestine-specific stem cells.
Dr. Wells said his team and other researchers around the world will be able to build on these findings. The process will be used as a tool to study normal intestinal development in humans and what goes wrong with the intestine in people with diseases.
Another important next step is to determine if the intestinal tissue is effective in transplant-based treatments of intestinal diseases such as short bowel syndrome. This approach is first being tested in animals in collaboration with co-author Noah Shroyer, Ph.D., and Michael Helmrath, M.S., M.D., a transplant surgeon at Cincinnati Children's. Ultimately, the researchers want to translate those methods into treatment for people.
The researchers said the study's findings will also facilitate studies to design better drugs that are more easily taken up by the body, since the intestine absorbs most drugs taken orally.
Also collaborating on the study from the Cincinnati Children's divisions of Developmental Biology, Hematology/Oncology, Pulmonary Biology and Gastroenterology, Hepatology and Nutrition were Scott Rankin, Matthew Kuhar, Jefferson, Vallance, Kathryn Tolle, Elizabeth Hoskins, Vladimir Kalinichenko and Aaron Zorn.
Primary funding support came from grants through the National Institutes of Health to Drs. James Wells and Zorn and from the Juvenile Diabetes Research Foundation.
About Cincinnati Children's
Cincinnati Children's Hospital Medical Center is one of just eight children's hospitals named to the Honor Roll in U.S. News and World Report's 2010-11 Best Children's Hospitals. It is ranked #1 for digestive disorders and highly ranked for its expertise in pulmonology, cancer, neonatology, heart and heart surgery, neurology and neurosurgery, diabetes and endocrinology, orthopedics, kidney disorders and urology. Cincinnati Children's is one of the top two recipients of pediatric research grants from the National Institutes of Health. It is internationally recognized for quality and transformation work by Leapfrog, The Joint Commission, the Institute for Healthcare Improvement, the federal Agency for Healthcare Research and Quality, and by hospitals and health organizations it works with globally. Additional information can be found at www.cincinnatichildrens.org.
Nick Miller | EurekAlert!
Two Group A Streptococcus genes linked to 'flesh-eating' bacterial infections
25.09.2017 | University of Maryland
Rainbow colors reveal cell history: Uncovering β-cell heterogeneity
22.09.2017 | DFG-Forschungszentrum für Regenerative Therapien TU Dresden
A warming planet
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
25.09.2017 | Power and Electrical Engineering
25.09.2017 | Health and Medicine
25.09.2017 | Physics and Astronomy